Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
This week’s blog tackles takeaways from the IMF Conference Series webinar — a discussion on key findings from the 2026 American Society of Clinical Oncology (ASCO), IMF International Myeloma Working Group (IMWG), and European Hematology Association (EHA) annual meetings. Patient questions were also addressed in the Q&A. READ THE BLOG.
Study results from the randomized, prospective phase III ENDURANCE (E1A11) trial, designed and conducted by the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN), were published today in the New England Journal of Medicine. The study was co-authored by several members of the International Myeloma Foundation (IMF) leadership who also serve on the ECOG-ACRIN Myeloma Committee, which led the study.
The phase III ENDURANCE trial results showed that two years of maintenance therapy with lenalidomide provides the same long-term survival benefit as indefinite treatment until progression for patients with standard-risk multiple myeloma. Read the full press release to learn more. READ THE PRESS RELEASE.
On July 9, 2026, the U.S. FDA "approved isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis U.S. LLC) for subcutaneous injection for multiple myeloma indications." LEARN MORE.
La próxima reunión del grupo de apoyo Las Voces de Mieloma se llevará a cabo en línea el 21 de julio de 2026, de 10:00 a. m. a 11:00 a. m. (hora Pacífico). El ponente invitado será el Dr. Cesar Rodriguez, profesor asociado de Medicina en la Escuela de Medicina Icahn de Mount Sinai y director clínico del Centro de Excelencia en Mieloma Múltiple. El Dr. Rodriguez hablará sobre el tema: "Cómo la inmunoterapia está cambiando el tratamiento del mieloma." REGÍSTRESE AQUÍ.
The next Las Voces de Mieloma Support Group will take place online on July 21, 2026, from 10 am - 11 am PST. Its Guest Speaker will be Dr. Cesar Rodriguez, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai and Clinical Director of the Multiple Myeloma Center of Excellence. Dr. Rodriguez will speak on the topic, "How immunotherapy is changing myeloma treatment." REGISTER HERE.
From August 18–24, 2026, intrepid cyclists — patients, care partners, and healthcare professionals — will cross Iceland’s breathtaking landscapes to raise vital funds for the International Myeloma Foundation’s mission.
